Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of cancer from an unknown primary.
Armstrong AC, Blackhall FH. Armstrong AC, et al. Expert Opin Pharmacother. 2007 Mar;8(4):445-55. doi: 10.1517/14656566.8.4.445. Expert Opin Pharmacother. 2007. PMID: 17309339 Review.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. André F, et al. Lancet Oncol. 2014 May;15(6):580-91. doi: 10.1016/S1470-2045(14)70138-X. Epub 2014 Apr 14. Lancet Oncol. 2014. PMID: 24742739 Clinical Trial.
Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
Grimmett C, Pickett K, Shepherd J, Welch K, Recio-Saucedo A, Streit E, Seers H, Armstrong A, Cutress RI, Evans DG, Copson E, Meiser B, Eccles D, Foster C. Grimmett C, et al. Patient Educ Couns. 2018 May;101(5):779-788. doi: 10.1016/j.pec.2017.11.016. Epub 2017 Nov 26. Patient Educ Couns. 2018. PMID: 29225062
Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations.
Grimmett C, Brooks C, Recio-Saucedo A, Armstrong A, Cutress RI, Gareth Evans D, Copson E, Turner L, Meiser B, Wakefield CE, Eccles D, Foster C. Grimmett C, et al. Support Care Cancer. 2019 Jan;27(1):297-309. doi: 10.1007/s00520-018-4307-x. Epub 2018 Jun 28. Support Care Cancer. 2019. PMID: 29955974
Cancer vaccines and immunotherapy.
Dermime S, Armstrong A, Hawkins RE, Stern PL. Dermime S, et al. Br Med Bull. 2002;62:149-62. doi: 10.1093/bmb/62.1.149. Br Med Bull. 2002. PMID: 12176857 Review.
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Board RE, et al. Among authors: armstrong ac. Breast Cancer Res Treat. 2010 Apr;120(2):461-7. doi: 10.1007/s10549-010-0747-9. Epub 2010 Jan 28. Breast Cancer Res Treat. 2010. PMID: 20107891
102 results